Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xifeng Huashi is a traditional Chinese medicine (TCM) formulation primarily used for the treatment of diarrheal irritable bowel syndrome (IBS-D). It is typically administered as granules and developed according to TCM principles, particularly those outlined in the "Expert Consensus on TCM Diagnosis and Treatment of Irritable Bowel Syndrome." The formula aims to regulate intestinal flora, reduce inflammation, and improve gastrointestinal symptoms. Clinical studies have shown that it can modulate cytokine levels such as IL-8 and 5-HT, thereby improving defecation patterns in IBS-D patients. The mechanism of action involves multi-target modulation typical of herbal formulas; specific molecular targets are not fully elucidated but may include anti-inflammatory pathways[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xifeng Huashi.